𝔖 Bobbio Scriptorium
✦   LIBER   ✦

The effect of 4-aminopyridine on clinical signs in multiple sclerosis: A randomized, placebo-controlled, double-blind, cross-over study

✍ Scribed by Harriët A. M. van Diemen; Dr. Chris H. Polman; Theo M. M. M. van Dongen; Arie C. van Loenen; Jos J. P. Nauta; Martin J. B. Taphoorn; Harm K. van Walbeek; Johan C. Koetsier

Publisher
John Wiley and Sons
Year
1992
Tongue
English
Weight
806 KB
Volume
32
Category
Article
ISSN
0364-5134

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Magnetic resonance imaging results of th
Magnetic resonance imaging results of the PRISMS trial: A randomized, double-blind, placebo-controlled study of interferon-β1a in relapsing-remitting multiple sclerosis
✍ David K. B. Li; Donald W. Paty 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 164 KB 👁 2 views

The PRISMS (Prevention of Relapses and Disability by Interferon-␤1a Subcutaneously in Multiple Sclerosis) trial was a doubleblind, randomized, multicenter, phase III, placebo-controlled study of interferon-␤1a in 560 patients from 22 centers in 9 countries with clinically definite or laboratory-supp

European/Canadian multicenter, double-bl
European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging–measured disease activity and burden in patients with relapsing multiple sclerosis
✍ Giancarlo Comi; Massimo Filippi; Jerry S. Wolinsky 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 698 KB

## Abstract Two prior double‐blind, placebo‐controlled, randomized trials demonstrated that glatiramer acetate (GA) reduces relapse rates in patients with relapsing remitting multiple sclerosis (RRMS). This study was designed to determine the effect, onset, and durability of any effect of GA on dis

The effects of rasagiline on cognitive d
The effects of rasagiline on cognitive deficits in Parkinson's disease patients without dementia: A randomized, double-blind, placebo-controlled, multicenter study
✍ Hasmet A. Hanagasi; Hakan Gurvit; Pınar Unsalan; Hilal Horozoglu; Nese Tuncer; A 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 113 KB 👁 2 views

## Abstract Cognitive impairment can occur at all stages of Parkinson's disease. Rasagiline is a selective monoamine oxidase type‐B inhibitor that enhances central dopaminergic transmission. Dopamine is thought to be involved in certain cognitive processes such as working memory. We assessed the ef

No Effect of the Calcium Antagonist, Isr
No Effect of the Calcium Antagonist, Isradipine, on Plasma Catecholamines in Irreversible Chronic Obstructive Pulmonary Disease (COPD). A Randomized, Double-blind, Placebo-controlled Study
✍ Niels A. Graudal; Anders M. Galløe; Inger Plum; Nils Milman; Jesper O. Clausen 📂 Article 📅 1995 🏛 Elsevier 🌐 English ⚖ 243 KB

SUMMARY: Calcium antagonists have been claimed to decrease the pulmonary artery pressure and increase oxygen uptake and cardiac output in patients with chronic obstructive pulmonary disease (COPD). This should tend to decrease the plasma levels of catecholamines. The purpose of the present study was